title: HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
abstract: Broadly neutralizing antibodies (bNAbs) have been isolated from selected HIV-1-infected individuals and shown to bind to conserved sites on the envelope glycoprotein (Env). However, circulating plasma virus in these donors is usually resistant to autologous isolated bNAbs, indicating that during chronic infection, HIV-1 can escape from even broadly cross-reactive antibodies. Here, we evaluate if such viral escape is associated with an impairment of viral replication. Antibodies of the VRC01 class target the functionally conserved CD4 binding site and share a structural mode of gp120 recognition that includes mimicry of the CD4 receptor. We examined naturally occurring VRC01-sensitive and -resistant viral strains, as well as their mutated sensitive or resistant variants, and tested point mutations in the backbone of the VRC01-sensitive isolate YU2. In several cases, VRC01 resistance was associated with a reduced efficiency of CD4-mediated viral entry and diminished viral replication. Several mutations, alone or in combination, in the loop D or β23-V5 region of Env conferred a high level of resistance to VRC01 class antibodies, suggesting a preferred escape pathway. We further mapped the VRC01-induced escape pathway in vivo using Envs from donor 45, from whom antibody VRC01 was isolated. Initial escape mutations, including the addition of a key glycan, occurred in loop D and were associated with impaired viral replication; however, compensatory mutations restored full replicative fitness. These data demonstrate that escape from VRC01 class antibodies can diminish viral replicative fitness, but compensatory changes may explain the limited impact of neutralizing antibodies during the course of natural HIV-1 infection.
  
  
  OBJECTIVE
  Some antibodies that arise during natural HIV-1 infection bind to conserved regions on the virus envelope glycoprotein and potently neutralize the majority of diverse HIV-1 strains. The VRC01 class of antibodies blocks the conserved CD4 receptor binding site interaction that is necessary for viral entry, raising the possibility that viral escape from antibody neutralization might exert detrimental effects on viral function. Here, we show that escape from VRC01 class antibodies can be associated with impaired viral entry and replication; however, during the course of natural infection, compensatory mutations restore the ability of the virus to replicate normally.
authors: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors: Rebecca M
authors: RM
authors: Lynch
authors: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors: Patrick
authors: P
authors: Wong
authors: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors: Lillian
authors: L
authors: Tran
authors: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors: Sijy
authors: S
authors: O'Dell
authors: Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors: Martha C
authors: MC
authors: Nason
authors: Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.
authors: Yuxing
authors: Y
authors: Li
authors: The Aaron Diamond AIDS Research Center, New York, New York, USA.
authors: Xueling
authors: X
authors: Wu
authors: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA john.mascola@nih.gov.
authors: John R
authors: JR
authors: Mascola
mesh_terms: D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000080908:Broadly Neutralizing Antibodies; D015704:CD4 Antigens / Q000276:immunology; D056084:Genetic Fitness / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D057131:Immune Evasion / Q000276:immunology*; D016297:Mutagenesis, Site-Directed; D009500:Neutralization Tests; D016415:Sequence Alignment; D017422:Sequence Analysis, DNA; D014759:Viral Envelope Proteins / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000080908:Broadly Neutralizing Antibodies; D015704:CD4 Antigens; D015483:HIV Antibodies; C578595:VRC01 monoclonal antibody; D014759:Viral Envelope Proteins
references: Cell Rep. 2014 May 8;7(3):785-95
references: 24767986
references: Immunity. 2014 May 15;40(5):657-68
references: 24768347
references: Cell. 2014 Jul 31;158(3):481-91
references: 25065977
references: Nature. 2014 Nov 6;515(7525):138-42
references: 25186731
references: J Mol Biol. 2001 Jun 8;309(3):657-70
references: 11397087
references: Virus Genes. 2001 Dec;23(3):281-90
references: 11778696
references: Nature. 2003 Mar 20;422(6929):307-12
references: 12646921
references: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
references: 12644702
references: Science. 2003 Sep 5;301(5638):1374-7
references: 12920303
references: AIDS. 1990 Feb;4(2):107-12
references: 2328092
references: AIDS Res Hum Retroviruses. 1990 Apr;6(4):465-79
references: 2187501
references: Virology. 1991 Jun;182(2):635-43
references: 1708933
references: Science. 1998 Jun 19;280(5371):1884-8
references: 9632381
references: J Virol. 2004 Dec;78(23):13232-52
references: 15542675
references: Virology. 2005 Mar 15;333(2):251-62
references: 15721359
references: J Virol. 2006 Oct;80(19):9586-98
references: 16973562
references: Nature. 2007 Feb 15;445(7129):732-7
references: 17301785
references: J Virol. 2007 Aug;81(15):8346-51
references: 17507468
references: Nat Med. 2007 Sep;13(9):1032-4
references: 17721546
references: J Immunol Methods. 2008 Jan 1;329(1-2):112-24
references: 17996249
references: Curr Protoc Immunol. 2005 Jan;Chapter 12:Unit 12.11
references: 18432938
references: Nature. 2008 May 29;453(7195):667-71
references: 18449194
references: J Virol. 2008 Aug;82(16):7932-41
references: 18524815
references: J Exp Med. 2010 Aug 30;207(9):1995-2002
references: 20679402
references: J Virol. 2010 Oct;84(20):10863-76
references: 20702642
references: J Virol. 2011 Nov;85(21):11502-19
references: 21849452
references: Science. 2011 Dec 2;334(6060):1289-93
references: 22033520
references: Adv Exp Med Biol. 2012;726:223-42
references: 22297516
references: J Virol. 2012 Apr;86(8):4394-403
references: 22345481
references: J Virol. 2012 May;86(10):5844-56
references: 22419808
references: PLoS Pathog. 2012;8(5):e1002721
references: 22693447
references: J Virol. 2012 Jul;86(14):7588-95
references: 22573869
references: Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90
references: 22745174
references: Immunity. 2012 Sep 21;37(3):412-25
references: 22999947
references: Immunol Rev. 2012 Nov;250(1):180-98
references: 23046130
references: J Virol. 2012 Dec;86(23):12676-85
references: 22973035
references: Nat Med. 2012 Nov;18(11):1688-92
references: 23086475
references: Nature. 2012 Nov 15;491(7424):406-12
references: 23151583
references: PLoS Pathog. 2012;8(11):e1003041
references: 23209412
references: Nature. 2012 Dec 6;492(7427):118-22
references: 23103874
references: J Biol Chem. 2012 Dec 14;287(51):43170-9
references: 23100255
references: J Exp Med. 2013 Apr 8;210(4):655-63
references: 23530120
references: Nature. 2013 Apr 25;496(7446):469-76
references: 23552890
references: Science. 2013 May 10;340(6133):711-6
references: 23539181
references: J Exp Med. 2013 Jun 3;210(6):1235-49
references: 23712429
references: Nat Struct Mol Biol. 2013 Jul;20(7):796-803
references: 23708606
references: PLoS One. 2013;8(7):e68863
references: 23874792
references: Immunity. 2013 Aug 22;39(2):245-58
references: 23911655
references: Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16538-43
references: 24043801
references: PLoS Pathog. 2013 Oct;9(10):e1003738
references: 24204277
references: J Virol. 2009 Jan;83(1):188-99
references: 18922865
references: Nature. 2009 Apr 2;458(7238):636-40
references: 19287373
references: PLoS Pathog. 2009 Apr;5(4):e1000365
references: 19343217
references: PLoS Pathog. 2009 Sep;5(9):e1000594
references: 19763269
references: PLoS Pathog. 2009 Sep;5(9):e1000598
references: 19763271
references: J Virol. 2009 Nov;83(21):11016-26
references: 19692480
references: Science. 2009 Oct 9;326(5950):285-9
references: 19729618
references: PLoS One. 2010;5(1):e8805
references: 20098712
references: Science. 2010 Aug 13;329(5993):811-7
references: 20616231
references: Science. 2010 Aug 13;329(5993):856-61
references: 20616233
references: J Virol. 2011 Jan;85(2):905-15
references: 20980495
references: J Virol. 2011 Sep;85(17):8954-67
references: 21715490
references: J Virol. 2011 Oct;85(19):9998-10009
references: 21795340
references: Science. 2011 Sep 16;333(6049):1633-7
references: 21764753
references: Science. 2011 Sep 16;333(6049):1593-602
references: 21835983
references: Nature. 2011 Sep 22;477(7365):466-70
references: 21849977
references: AIDS. 2014 Jan 14;28(2):163-9
references: 24361678
references: Nature. 2014 May 1;509(7498):55-62
references: 24590074